Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001346302-19-000040
Filing Date
2019-11-07
Accepted
2019-11-07 16:36:39
Documents
59
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q q32019form10-q.htm 10-Q 1465755
2 EXHIBIT 31.1 q32019exhibit311.htm EX-31.1 13591
3 EXHIBIT 31.2 q32019exhibit312.htm EX-31.2 13672
4 EXHIBIT 32.1 q32019exhibit321.htm EX-32.1 10485
  Complete submission text file 0001346302-19-000040.txt   5300346

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT xers-20190930.xml EX-101.INS 896658
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xers-20190930.xsd EX-101.SCH 38657
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT xers-20190930_cal.xml EX-101.CAL 27648
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT xers-20190930_def.xml EX-101.DEF 230785
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xers-20190930_lab.xml EX-101.LAB 494695
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xers-20190930_pre.xml EX-101.PRE 307727
Mailing Address 180 NORTH LASALLE STREET STE 1800 CHICAGO IL 60601
Business Address 180 NORTH LASALLE STREET STE 1800 CHICAGO IL 60601 512-498-2670
XERIS PHARMACEUTICALS INC (Filer) CIK: 0001346302 (see all company filings)

EIN.: 203352427 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38536 | Film No.: 191200909
SIC: 2834 Pharmaceutical Preparations